78 related articles for article (PubMed ID: 18593345)
21. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
22. Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures.
Boucher S; Recordon-Pinson P; Neau D; Ragnaud JM; Titier K; Faure M; Fleury H; Masquelier B
J Clin Virol; 2005 Dec; 34(4):288-94. PubMed ID: 16286052
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
24. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
25. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.
Bon I; Gibellini D; Borderi M; Alessandrini F; Vitone F; Schiavone P; Re MC
J Clin Virol; 2007 Apr; 38(4):313-20. PubMed ID: 17306618
[TBL] [Abstract][Full Text] [Related]
26. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
27. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
[TBL] [Abstract][Full Text] [Related]
28. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART.
Monno L; Punzi G; Scarabaggio T; Saracino A; Brindicci G; Fiore JR; Iambrenghi OC; Di Stefano M; Pastore G; Angarano G
J Med Virol; 2003 May; 70(1):1-9. PubMed ID: 12629636
[TBL] [Abstract][Full Text] [Related]
29. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
Murphy MD; Marousek GI; Chou S
J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
[TBL] [Abstract][Full Text] [Related]
30. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
[TBL] [Abstract][Full Text] [Related]
31. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
[TBL] [Abstract][Full Text] [Related]
32. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J
J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209
[TBL] [Abstract][Full Text] [Related]
33. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
[TBL] [Abstract][Full Text] [Related]
34. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
35. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
36. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
Chantratita W; Jenwitheesuk E; Watitpun C; Pongthanapisith V; Vibhagool A; Leechawengwong M; Sookpranee M; Apairatana A
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):80-4. PubMed ID: 12118466
[TBL] [Abstract][Full Text] [Related]
38. Zero prevalence of primary drug resistance-associated mutations to protease inhibitors in HIV-1 drug-naive patients in and around Aligarh, India.
Azam M; Malik A; Rizvi M; Rai A
J Infect Dev Ctries; 2014 Jan; 8(1):79-85. PubMed ID: 24423716
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
40. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
